Daniel Condie, MD
Dermatology · Gilbert, AZNPI 1336536143
Payments from drug & device makers
Across 297 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Kerecis Limited$1K
- Lilly USA, LLC$686
- Johnson & Johnson$668
- Regeneron Healthcare Solutions, Inc.$550
- Sun Pharmaceutical Industries Inc.$479
- plus $3K from 28 others
What the payments were for
- Consulting fees$1752%
- Food & beverage$8,00998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $1,349 |
| Kerecis Limited | 6 | $1,197 |
| Lilly USA, LLC | 28 | $686 |
| Johnson & Johnson | 29 | $668 |
| Regeneron Healthcare Solutions, Inc. | 21 | $550 |
| Sun Pharmaceutical Industries Inc. | 23 | $479 |
| Novartis | 16 | $365 |
| Prugen, Inc. Pharmaceuticals | 2 | $350 |
| Amgen | 15 | $301 |
| LEO Pharma Inc. | 13 | $296 |
| UCB, Inc. | 15 | $240 |
| Arcutis Biotherapeutics, Inc. | 6 | $237 |
| Bioventus LLC | 2 | $199 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $184 |
| Incyte Corporation | 9 | $181 |
| Eli Lilly | 1 | $175 |
| Organon | 7 | $99 |
| Almirall LLC | 6 | $92 |
| Galderma Laboratories, L.p. | 5 | $89 |
| Organogenesis Inc. | 3 | $77 |
| Boehringer Ingelheim | 3 | $63 |
| Sanofi | 2 | $47 |
| Journey Medical Corporation | 2 | $33 |
| Pfizer | 2 | $33 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| Botanix SB Inc | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Biofrontera Inc. | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$4,182
- Kerecis GraftGuide$1,046
- Rinvoq$231
- ZORYVE$124
- Tremfya$121
How this compares
$8,184 in reported general payments places this provider in the 75th percentile of 305 dermatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 30 | $1,156 |
| Cephalexin | 238 | $662 |
| Doxycycline Monohydrate | 62 | $603 |
| Mupirocin | 38 | $282 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $93 |
| Clindamycin Hcl | 27 | $82 |
| Tramadol Hcl | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Gilbert
- Ali RkeinGilbert$1.3M
- John KastelerGilbert$456K
- Sam SmithGilbert$39K
- Matthew WoodsGilbert$17K
- Catherine Chen TsaiGilbert$12K
- Kenneth SteilPhoenix$15.6M
- Lindsay AckermanPhoenix$7.4M
- Sadra JazayeriPhoenix$5.2M
- Aaron MangoldScottsdale$4.9M
- James PehoushekGlendale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.